Clinical trials
Carboplatin clinical trials
Below are recruiting carboplatin clinical trials, each written for real people, not researchers. We’re tracking 484 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06123884RecruitingPhase 2/Phase 3
BAT1308 plus chemotherapy for PD-L1-positive cervical cancer
This clinical trial tests a new combination therapy (BAT1308 plus chemotherapy, with or without Avastin) for women with advanced cervical cancer that is PD-L1-positive and has not been previously treated with systemic therapy. The goal is to see if this combination can shrink tumors or slow disease progression.
Wuhan, HubeiAges 18–70 - NCT06145308RecruitingPhase 2
Precision treatment for salivary gland cancer
This trial tests a personalized treatment approach for recurrent or metastatic salivary gland cancer. It uses special tests on your tumor to find the best targeted therapy for your specific cancer type.
Beijing, Beijing MunicipalityAges 18–100 - NCT06209294RecruitingPhase 2
New drug combo before fertility-sparing surgery for cervical cancer
This trial tests a combination of immunotherapy (AK104) and standard chemotherapy before surgery for a certain type of early-stage cervical cancer. The goal is to see if this approach can help shrink the tumor enough to allow fertility-preserving surgery, so you may be able to keep your uterus.
Shanghai, Shanghai MunicipalityAges 18–45 - NCT06227117RecruitingPhase 2
Study of DV and Toripalimab before surgery for HER2-low breast cancer
This trial tests a combination of two drugs (DV and Toripalimab) with chemotherapy before surgery for a specific type of breast cancer (HER2-low, HR-negative) that has not spread too far. The goal is to see if this approach can shrink the tumor and improve outcomes.
Changsha, HunanAges 18 years+ - NCT06236438RecruitingPhase 2/Phase 3
Livmoniplimab plus budigalimab and chemo for untreated lung cancer
This trial tests a new combination of two immune system drugs (livmoniplimab and budigalimab) plus standard chemotherapy compared to the current standard treatment (pembrolizumab plus chemo) for people with advanced non-small cell lung cancer that has not been treated yet. The goal is to see if the new combination works better at controlling the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06245889RecruitingPhase 2
PET-Guided Therapy for Triple-Negative Breast Cancer
This trial tests whether a special PET scan can help guide the best combination of chemotherapy and immunotherapy before surgery for patients with triple-negative breast cancer. It aims to personalize treatment and improve outcomes.
Baltimore, MarylandAges 18 years+ - NCT06279364RecruitingPhase 3
Testing SKB264 vs standard chemo for advanced triple-negative breast cancer
This trial tests a new drug called SKB264 against standard chemotherapy options for people with advanced triple-negative breast cancer who have not yet received chemotherapy for their advanced disease. The goal is to see if SKB264 works better than the usual treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06291064RecruitingPhase 2
Chemotherapy study for Nigerian women with triple-negative breast cancer
This trial studies a standard chemotherapy treatment for Nigerian women with triple-negative breast cancer that has not spread widely. It aims to see how well the treatment works and how safe it is.
Ikeja, LagosAges 18–70 - NCT06292286Recruiting
Second surgery for recurrent ovarian cancer that responds to platinum
This trial tests whether having a second surgery after initial treatment can help people with ovarian cancer that came back but still responds to platinum-based chemotherapy. It may offer another option to remove remaining tumors and delay further treatments.
Hong KongAges 18 years+ - NCT06304350RecruitingPhase 2
Pembrolizumab plus chemo before surgery for esophageal cancer
This trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (given before surgery) can help shrink stage II/III esophageal cancer. The goal is to make surgery more likely to remove all cancer and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06309745Recruiting
Lowering treatment for Stage II testicular cancer
This trial tests lowering the intensity of treatment (de-escalation) for Stage II seminoma, a type of testicular cancer. You may receive either a surgery to remove lymph nodes or a single round of chemotherapy (carboplatin), instead of more aggressive standard treatments, to see if it's safe and effective.
LondonAges 16 years+ - NCT06323460RecruitingPhase 2
Less Radiation for HPV Throat Cancer Guided by a Blood Test
This study tests a way to use less radiation for HPV-related throat cancer. Doctors will adjust your treatment based on a simple blood test that tracks cancer DNA, so you may get only the treatment you need.
Columbus, OhioAges 18 years+ - NCT05281471RecruitingPhase 3
Tested drug for platinum-resistant ovarian cancer with bevacizumab
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
Mobile, AlabamaAges 18 years+ - NCT06422143RecruitingPhase 3
Keytruda with or without Sac-TMT for advanced squamous lung cancer
This trial tests the combination of pembrolizumab (Keytruda) with or without a new drug, sacituzumab tirumotecan (Sac-TMT), as initial treatment for advanced squamous non-small cell lung cancer. It aims to see if adding Sac-TMT after initial treatment helps keep cancer under control longer.
Little Rock, ArkansasAges 18 years+ - NCT02813135RecruitingPhase 1/Phase 2
Targeted cancer treatment chosen by a tumor’s genetic findings
This early-phase trial tests a treatment plan that uses results from genetic testing of your tumor to choose the best targeted therapy. It may help people whose cancer has come back or does not respond to standard treatment by matching treatment to specific tumor changes.
CopenhagenAges Up to 18 years - NCT06312137RecruitingPhase 3
Pembrolizumab with or without another drug for lung cancer after surgery
This trial tests adding a new drug (sacituzumab tirumotecan) to pembrolizumab for people with non-small cell lung cancer that did not completely disappear after initial treatment and surgery. The goal is to see if the combination works better than pembrolizumab alone.
Little Rock, ArkansasAges 18 years+ - NCT06364917RecruitingPhase 2
Comparing two immunotherapy options for PD-L1 negative lung cancer
This trial tests whether using two immunotherapy drugs together works better than a single drug for people with advanced non-small cell lung cancer that does not have the PD-L1 protein. The study aims to find a more effective treatment for this specific type of lung cancer.
Birmingham, AlabamaAges 18–89 - NCT06400472RecruitingPhase 1
Study of LY4170156 for advanced solid tumors
This study tests a new drug called LY4170156 for people with certain advanced solid tumors. It aims to see if the drug is safe and how well it works.
Scottsdale, ArizonaAges 18 years+ - NCT06403878RecruitingPhase 2
Chemo-immunotherapy before surgery for older adults with esophageal cancer
This trial tests whether giving chemotherapy and immunotherapy before surgery is safe and effective for older adults (70+) with a certain type of esophageal cancer. It aims to find a treatment approach that works well for patients who haven't had cancer treatment before.
ChengduAges 70–100 - NCT06405230RecruitingPhase 1/Phase 2
Study of Immunotherapy Response in Returned Lung Cancer
This trial tests how well a new imaging method and lab-grown tumor models can predict response to immunotherapy in people with non-small cell lung cancer that has returned after initial surgery. Participants will receive standard immunotherapy, and researchers will study their tumor samples and scans.
LondonAges 30 years+ - NCT06417814RecruitingPhase 3
Study of Dato-DXd with or without osimertinib for EGFR-mutated lung cancer
This trial tests a new drug, Dato-DXd, given alone or with osimertinib, versus standard chemotherapy for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) that has worsened after osimertinib treatment.
Fayetteville, ArkansasAges 18–130 - NCT06420973RecruitingPhase 2
Testing RC48 for ovarian cancer returning after platinum treatment
This trial tests a new drug, RC48, for people with ovarian cancer that came back after responding well to platinum chemotherapy. RC48 targets the HER2 protein on cancer cells, which may stop the tumor from growing. Researchers want to see if it's safe and works better than current options.
Beijing, Beijing MunicipalityAges 18–75 - NCT06431633RecruitingPhase 3
Sacituzumab and zimberelimab for lung cancer after surgery
This trial tests a combination of two drugs (sacituzumab and zimberelimab) for people with non-small cell lung cancer that was confined to the chest, was surgically removed, but not completely cleared by prior chemotherapy and immunotherapy. The goal is to see if this treatment can help prevent the cancer from coming back.
Alicante, AlicanteAges 18 years+ - NCT06439225RecruitingPhase 3
Chemo for prostate cancer with DNA repair changes
This trial tests a combination of two chemotherapy drugs (carboplatin and docetaxel) for men whose prostate cancer has spread and has specific changes in DNA repair genes. It aims to see if this treatment can help when other hormone therapies have stopped working.
Calgary, AlbertaAges 18 years+
Hear when a new Carboplatin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carboplatin?
- Yes. Clin2 currently lists 484 recruiting carboplatin studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carboplatin trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carboplatin trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.